Of note, upgrading a case of higher risk MDS or MDS/MPN to a definitive NPM1-mutated AML diagnosis, based upon molecular and/or immunohistochemical analyses, could have relevant consequences on therapeutic algorithm. Here, NPM1 is linked to myelodysplastic syndrome.